Remedies, a part of the Zydus Group, has launched Interferon beta-1b under
the brand name ''Betaferon'' for the first time in India for the treatment of
multiple sclerosis (MS). Betaferon is a subcutaneous injection and is the
only Interferon efficacious even in the secondary progressive stages of multiple
sclerosis. The product is being marketed in collaboration with Schering AG,
Sclerosis is a chronic degenerative disease of the central nervous system
and occurs chiefly in young adults between 20 to 50 years and results in patients
slowly losing control over their bodies.
was launched in the US in 1993. This pioneering drug was a breakthrough effort
in the treatment of multiple sclerosis. It is estimated that 1.5 million people
suffer from multiple sclerosis worldwide. Betaferon is the top global product
of Schering AG with over 2,00,000 patients on this treatment worldwide, registering
sales of 780 million Euros in the year 2004.
launch of Betaferon is yet another step towards a strong collaborative enterprise
between Zydus and Schering AG in offering innovative healthcare therapies
in the fields of female healthcare,
cancer therapy and radiology," said J C Jani, executive director of Zydus
Cadila and head of German Remedies.